In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade.
AstraZeneca announced in late May it plans to raise revenues from $45.8 billion in 2023 to $80.billion in 2030, as well as release 20 new drugs by then."Biology is complicated, and we're never sure of anything. But we have a great level of confidence we can get there, and I think this target forces us to think creatively and be ambitious and stretch," Soriot said."But we have a large portfolio of existing products, several blockbusters...
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer: